Joshua Suri is a seasoned executive with over 40 years of experience in the healthcare industry in positions including R&D, medical information, territory sales, sales training, marketing and sales analysis, brand lead, sales management, and leading and revitalizing Schering’s Dermatology Division.

While at Novartis, he spearheaded the company’s pre-commercialization epilepsy and stroke products.

In 1999, Joshua left the corporate world to start his medical strategic consulting and communications company; The Westfield Group (Wg).

During his leadership at Wg, the company grew quickly and helped market and commercialize dozens of products, including blockbusters, i.e., Claritin, Celebrex, Lovenox, and many more.

Joshua holds a BS in Pharmacy from Rutgers College of Pharmacy and started his doctoral work in pharmacology at UMDNJ- GSBS (uncompleted PhD).